Welcome to our dedicated page for Angiodynamics news (Ticker: ANGO), a resource for investors and traders seeking the latest updates and insights on Angiodynamics stock.
AngioDynamics, Inc. (NASDAQ: ANGO) is a medical technology company whose news flow centers on vascular interventions, oncology technologies, and corporate developments. Company announcements emphasize its focus on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients.
News releases frequently highlight performance across AngioDynamics’ two main platforms, Med Tech and Med Device. Investors can follow updates on Med Tech growth, including results from the Auryon peripheral atherectomy platform, the Mechanical Thrombectomy business (AngioVac and AlphaVac), and the NanoKnife irreversible electroporation platform. Earnings reports describe trends in Med Tech and Med Device net sales, gross margin, and the use of non‑GAAP measures such as adjusted EBITDA and pro forma results.
AngioDynamics also issues news about regulatory milestones and clinical studies. Recent items include FDA IDE approvals for the APEX‑Return study evaluating the AlphaReturn Blood Management System with AlphaVac F1885 in acute pulmonary embolism, and the PAVE clinical study assessing the AngioVac System for right‑sided infective endocarditis. The company has reported FDA 510(k) clearance for a modified AlphaVac F1885 System with expanded indications, as well as publication of the PRESERVE study of the NanoKnife System for prostate tissue ablation in European Urology.
Additional news topics include recognition of the NanoKnife System on TIME’s 2025 Best Inventions list, enrollment milestones in trials such as AMBITION BTK and RECOVER‑AV, participation in investor conferences, and scheduling of quarterly earnings calls. For investors and observers, the ANGO news stream offers insight into product performance, clinical evidence, regulatory progress, and the company’s strategic focus on Med Tech growth.
AngioDynamics (NASDAQ: ANGO) announced that President and CEO Jim Clemmer will present at the Leerink Partners Global Healthcare Conference on Monday, Mar. 9, 2026 at 1:40 p.m. ET. A live webcast will be available via the company’s Investors website and a replay will be posted after the event.
AngioDynamics (NASDAQ: ANGO) announced expanded European indications for its NanoKnife System on February 19, 2026, adding soft tissue ablation for tumors of the liver, pancreas, kidney, and prostate, including intermediate-risk prostate cancer.
The move broadens physician access to NanoKnife's irreversible electroporation (IRE) non-thermal ablation technology and the company will launch the LIVER-IRE Global Registry to collect prospective real-world liver tumor outcomes.
AngioDynamics (NASDAQ: ANGO) and The PERT Consortium launched the ALPHA-PE Research Fund to support investigator-led pulmonary embolism (PE) research. Awards range from $50,000 to $750,000 over one to three years to fund real-world, physician-driven studies addressing PE evidence gaps and patient outcomes.
The program invites Letters of Intent followed by full proposals for selected applicants and is intended to generate clinically relevant real-world evidence to inform PE care.
AngioDynamics (NASDAQ: ANGO) will host its third Cardiovascular Scientific Forum Feb 6–8, 2026, to convene interventional cardiologists, surgeons, and researchers for physician-led collaboration, hands-on workshops, and investigator meetings focused on evidence generation across the cardiovascular portfolio.
Recent regulatory milestones include Nov 2025 FDA IDE approval for the APEX-Return pivotal study (AlphaReturn with AlphaVac F1885, up to 40 patients), Nov 2025 FDA 510(k) clearance for a modified AlphaVac F1885, and Nov 2025 IDE approval for the PAVE pilot (AngioVac, up to 30 patients), building clinical evidence for PE, VTE, and right-heart vegetation removal.
AngioDynamics (NASDAQ: ANGO) reported fiscal Q2 2026 results: net sales $79.4M (+8.8% pro forma) and Med Tech sales $35.7M (+13.0%). GAAP net loss was $6.4M (loss per share $0.15) and adjusted loss per share was $0.00. Adjusted EBITDA was $5.9M and cash was $41.6M.
The company secured three regulatory milestones for its Mechanical Thrombectomy portfolio (APEX-Return IDE, PAVE IDE, modified AlphaVac 510(k)), concluded patent litigation with Bard, and raised FY2026 net sales guidance to $312–$314M and adjusted EBITDA to $8–$10M. CEO Jim Clemmer will retire upon successor appointment expected in fiscal 2027.
AngioDynamics (NASDAQ: ANGO) will report fiscal 2026 second quarter results before the market open on Tuesday, January 6, 2026. Management will host a conference call at 8:00 AM ET the same day to discuss results. Investors can join by dialing 1-877-407-0784 (domestic) or +1-201-689-8560 (international) or via webcast in the company Investors section at www.angiodynamics.com.
A webcast replay will be available about one hour after the call and a recorded playback will be accessible until Tuesday, January 13, 2026 at 11:59 PM ET by dialing 1-844-512-2921 (domestic) or +1-412-317-6671 (international) using passcode 13757614.
AngioDynamics (NASDAQ: ANGO) announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 14, 2026.
The presentation will begin at 3:00 p.m. PT. A live webcast will be accessible via the company’s Investors section at www.angiodynamics.com and will be available for replay after the event.
AngioDynamics (NASDAQ: ANGO) announced that CEO Jim Clemmer and CFO Stephen Trowbridge will participate in a fireside chat at the UBS Global Healthcare Conference on Monday, Nov. 10, 2025 at 8:00 a.m. ET. A live webcast will be available via the company’s Investors webpage and a replay will be posted after the event.
The presentation offers investors a chance to hear management discuss strategy, financial priorities, and market outlook for the company.
AngioDynamics (NASDAQ: ANGO) said its NanoKnife System was named to TIME’s 2025 Best Inventions in Medical and Healthcare for its use of Irreversible Electroporation (IRE) to ablate prostate tissue while preserving nearby structures.
The company noted a U.S. FDA 510(k) clearance in late 2024, publication of the PRESERVE study (121 patients, 17 sites) showing 84% free from in-field clinically significant disease at 12 months, 96% pad-free continence preservation, and 84% retention of baseline sexual function. AngioDynamics referenced >2,600 global patients treated and said the TIME issue hits newsstands December 12.
AngioDynamics (NASDAQ: ANGO) reported strong fiscal Q1 2026 results, with net sales reaching $75.7 million, up 12.2% year-over-year. The Med Tech segment showed exceptional performance with 26.1% growth to $35.3 million, marking its fourth consecutive quarter of over 20% growth.
Key financial metrics include a gross margin of 55.3%, adjusted EBITDA of $2.2 million (compared to -$0.2M prior year), and adjusted loss per share of $0.10. The company ended Q1 with $38.8 million in cash and maintains a debt-free balance sheet.
Following strong performance, AngioDynamics raised its FY2026 guidance, now expecting net sales of $308-313 million and Med Tech growth of 14-16%. The company achieved significant clinical milestones with first patient enrollments in both AMBITION BTK and RECOVER-AV trials, while the NanoKnife PRESERVE study results were published in European Urology.